🔎 Trials Near Me

Home › Malattia di Crohn › North Carolina

Studi clinici su Malattia di Crohn nello stato di North Carolina

20 studi su Malattia di Crohn cercano partecipanti presso sedi nello stato di North Carolina.

Città nello stato di North Carolina

Testo ufficiale dello studio (inglese)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • University of North Carolina Medical Center ( Site 5034), Chapel Hill
  • Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Digestive Health Partners /ID# 280490, Asheville
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
  • Carolina Digestive Diseases, Greenville
  • Piedmont Healthcare, Statesville
  • e altri 1
In reclutamentoFase 4
Età da 18 a 80 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina, Chapel Hill
  • Atrium Health, Charlotte
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07196722

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Coastal Research Institute - Fayetteville, Fayetteville
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
  • OnSite Clinical Solutions-Site Number: 8400051, Charlotte
  • Duke University Medical Center-Site Number: 8400093, Durham
  • e altri 3
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
  • Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07184944

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  • Cross Creek Medical Clinic, Fayetteville
  • Peters Medical Research, High Point
  • Wake Research Associates, Raleigh
In reclutamentoFase 2
Età da 18 a 85 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06226883

A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

  • University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoFase 4
Età 18 e oltre · Donne · Aggiornato il 28 ago 2026 · NCT07654751

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina Hospital, Chapel Hill
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT07577843

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of North Carolina, Chapel Hill
  • Atrium Health Center for Gastroenterology and Surgery, Charlotte
  • Wake Forest School of Medicine, Winston-Salem
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07237516

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

  • University of North Carolina at Chapel Hill, Chapel Hill
In reclutamento
Età da 18 a 44 · Donne · Aggiornato il 14 lug 2026 · NCT07337902

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Univ NC Chapel Hill /ID# 262198, Chapel Hill
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Levine Children's, Charlotte
In reclutamentoFase 4
Età da 6 a 17 · Tutti i sessi · Aggiornato il 27 mag 2026 · NCT05781152

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Atrium Health, Charlotte
  • Duke Health System, Durham
In reclutamentoStudio osservazionale
Età da 1 a 18 · Tutti i sessi · Aggiornato il 17 apr 2026 · NCT07198113

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

  • Investigational Site Number: 8400003, Chapel Hill
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 27 mar 2026 · NCT06958536

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, High Point
  • Mirador Therapeutics Selected Site, Raleigh
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 12 mar 2026 · NCT07113522

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

  • Evidera, a PPD Business Unit /ID# 238688, Morrisville
In reclutamentoStudio osservazionale
Tutte le età · Donne · Aggiornato il 17 lug 2025 · NCT04846959

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.